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Abstract Advances in our understanding of the basic biology and biochemistry of chromatin
structure and function at genome scales has led to tremendous growth in the fields of epigenomics
and transcriptional biology. While it has long been appreciated that transcriptional pathways are
dysregulated in failing hearts, only recently has the idea of disrupting altered transcription by
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targeting chromatin-associatedproteinsbeenexplored.Here,weprovide abrief overviewof efforts
to drug transcription in the context of heart failure, focusing on the bromo- and extra-terminal
domain (BET) family of chromatin co-activator proteins.
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Abstract figure legend Stress- or injury-induced cardiac signalling cascades converge on the nucleus to trigger global
shifts in gene expression that contribute to the cycle of adverse remodelling and impaired function of the heart.
Current pharmacological therapies target a very proximal step in stress-dependent cardiac signalling (e.g. antagonists
of the β1 adrenergic receptor). As transcription factors and the chromatin regulatory apparatus act as the terminal
signal integrators that transduce these signals into changes in cell identity, disrupting altered transcription by targeting
chromatin-associated proteins has emerged as an exciting potential therapeutic avenue.
Heart failure (HF) is an extremely common clinical
syndrome characterized by symptomsof fatigue, shortness
of breath and ankle swelling that result from structural
or functional cardiac abnormalities that lead to elevated
intracardiac pressures with or without a reduced cardiac
output. This condition is a leading cause of morbidity
and mortality affecting approximately 2% of the adult
population worldwide (Mosterd et al. 1999; Redfield et al.
2003; Bleumink et al. 2004; Writing Group Members
et al. 2016; Metra & Teerlink, 2017). The calculated
lifetime risk of developing HF is a staggering 20%
with the prevalence projected to increase by 25% over
the next 20 years, statistics attributed to our ageing
populace as well as our ability to stabilize acute cardio-
vascular events (Lloyd-Jones et al. 2002; Heidenreich
et al. 2013; Metra & Teerlink, 2017). The burden of
HF-associated care is high, comprising 2–3% of the
total expenditure of healthcare systems in high-income
countries (Heidenreich et al. 2013).Despite this enormous
expenditure, the prognosis of HF remains dire with poor
quality of life, high rates of hospital admission, and
a worse survival than patients with several common
and dreaded solid tumours (Braunwald, 2013; Writing
Group Members et al. 2016; Mamas et al. 2017). Despite
current pharmacotherapeutic approaches, which largely
involve blockade of circulating neurohormone activity, a
diagnosis of HF carries a 5-year mortality rate of nearly
50%, underscoring the urgent need for new treatments
(Writing Group Members et al. 2016; Taylor et al.
2017). A large body of experimental and clinical data
demonstrate that the process of stress-induced cardiac
remodelling is a maladaptive feature of HF pathogenesis
(Hill & Olson, 2008; van Berlo et al. 2013). As such,
the molecular effectors that drive contractile dysfunction
and pathological cardiac remodelling, many of whichmay
originate within non-myocyte cell types (Kanisicak et al.
2016;Khalil et al.2017;Molkentin et al.2017; Fu et al.2018;
Honold & Nahrendorf, 2018; Nahrendorf, 2018; Swirski
& Nahrendorf, 2018; Valiente-Alandi et al. 2018), have
been increasingly recognized as attractive targets for the
development of new therapeutic interventions (McKinsey
& Olson, 2005; Hill & Olson, 2008; van Berlo et al. 2013).
In the context of HF, stress-activated cardiac signalling
cascades converge on defined transcriptional pathways,
an event that triggers broad shifts in cellular gene
expression programmes. These stress-activated gene
expression programmes drive cellular hypertrophy, inter-
stitial fibrosis and inflammation, processes that fuel a
vicious cycle of structural cardiac remodelling and contra-
ctile dysfunction (Hill & Olson, 2008; van Berlo et al.
2013). Current standard of care pharmacological therapies
for systolicHF exert their salubrious effects bymodulating
a very proximal step in signal transduction, largely
via antagonizing the effect of stress-activated neuro-
hormones on their cognate receptors (e.g. antagonists
of the β1 adrenergic receptor and blockade of
renin–angiotensin signalling) (Metra & Teerlink, 2017).
As the nuclear gene-regulatory machinery functions
as a distal signal integrator in this disease process,
defining the mechanisms by which upstream pathways
couple to chromatin-dependent gene transcription in the
diseased adult heart has been an area of intense scientific
and therapeutic interest. Of these chromatin-based
mechanisms, the dynamic acetylation of lysine residues
in the tails of core nucleosome histone proteins and
in transcription factors, a process regulated by histone
acetyltransferase (HAT) and histone deacetylase (HDAC)
enzymes, has been recognized to play a central role in
HF pathogenesis (McKinsey & Olson, 2005; McKinsey,
2012; Di Salvo & Haldar, 2014). However, we have only
recently begun to appreciate the precise signalling events
downstream of local chromatin acetylation in HF and
the potential to target the transcription machinery as a
novel therapeutic approach. Here, we provide a concise
review of the state-of-the-art in drugging transcription
in heart failure with a particular focus on the bromo-
and extra-terminal domain (BET) family of chromatin
co-activator proteins.
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Chromatin and epigenetic control of gene expression
Chromatin is the macromolecular complex of nucleic
acids and proteins in which the linear DNA of the
mammalian genome is packaged in the nucleus of each
cell (Hargreaves & Crabtree, 2011). The primary unit of
chromatin is the core nucleosome particle composed of an
octamer of four different histone proteins around which
double-stranded DNA is wrapped (Luger et al. 1997).
This primary chromatin is subsequently organized into
dynamic higher order structures that allow state-specific
genomic accessibility and dynamic signalling function
(Schreiber & Bernstein, 2002). The term ‘epigenetics’
refers to the layer of information that exists above (‘epi’)
that which is encoded by the DNA sequence (‘genetic’),
thus allowing the genome to function distinctively in
different cell types (Greally, 2018). The epigenome
comprises all of the sequence-independent processes (e.g.
post-translational modification of histone tails) that act in
the context of chromatin to modulate cell state-specific
gene expression (Di Salvo & Haldar, 2014). Cellular
state is orchestrated by precise spatiotemporal control
of gene expression and is executed by defined trans-
criptional signalling events involving alterations in local
chromatin structure, dynamic interactions between DNA
binding transcription factors (TFs) with their cognate
cis-regulatory elements (e.g. enhancers and promoters),
and the assembly of the general transcriptional machinery
and associated cofactors (Lee & Young, 2013; Soshnev
et al. 2018). Acetylation of specific lysine residues on
histones and other chromatin-associated proteins is a
critical post-translational modification that governs gene
transactivation and serves as a docking site for epigenetic
‘reader’ proteins, which contain the evolutionarily
conserved bromodomain (BD) acetyl-lysine recognition
module (Zeng & Zhou, 2002; Berger, 2007). Following
recognition of discrete patterns of acetylation marks,
BD-containing proteins play key roles in transcriptional
signalling via their intrinsic enzymatic activity (e.g.
E1A binding protein p300 (EP300), switch/sucrose non-
fermentable (SWI/SNF)) or their ability to recruit
multifunctional protein complexes that signal to the
general transcription machinery (as is the case for BRD4)
(Haynes et al. 1992; Goodman & Smolik, 2000; Jang et al.
2005; Yang et al. 2005). We posit that the mechanisms
by which hyperacetylated cardiac enhancers signal down-
stream toRNApolymerase II (Pol II) at the transcriptional
start sites of stress-activated cardiac genes may be a novel
druggable space in HF.
The BET family of epigenetic ‘reader’ proteins and the
small molecule BET inhibitor JQ1
The mammalian BET family of proteins comprises BRD2,
BRD3, BRD4 and BRDT (Taniguchi, 2016). Encoded
by paralogous genes, these proteins are characterized
by two tandem BDs in their N-terminal region and a
C-terminal extra-terminal (ET) domain (Jung et al. 2014;
Taniguchi, 2016). The BD is a conserved sequence of
approximately 110 amino acids that forms four α-helices
(Z, A, B, C) and two interconnected loops (ZA, BC) that
form a hydrophobic pocket to encompass a recognition
site for acetylated lysine (Zeng & Zhou, 2002; Berger,
2007). The ET domain is an approximately 80 amino acid
conserved region whose function is poorly understood,
but is likely involved in scaffolding transcription effector
proteins (Rahman et al. 2011). BRD2, BRD3 and BRD4
are ubiquitously expressed in developing and adult tissues
withBRDTexpression limited to the testis (Taniguchi et al.
2001; Shang et al. 2004). Of note, both BRD4 and BRDT
differ fromother BET familymembers in that they contain
a conserved, 40 amino acid C-terminal domain (CTD)
that interacts with and allosterically activates positive
transcription elongation factor b (P-TEFb) (Jang et al.
2005; Yang et al. 2005). P-TEFb is a kinase complex that
phosphorylates serine residues in the Pol II C-terminal
heptapeptide repeats as well as on other pause-control
factors to drive productive transcriptional elongation
(Bisgrove et al. 2007; Schroder et al. 2012; Itzen et al.
2014). Of the BET family, BRD4 has been most intensely
studied given its role in the pathogenesis of many cancers
(French et al. 2003; Filippakopoulos et al. 2010; Delmore
et al. 2011; Zuber et al. 2011; Rodriguez et al. 2012;
Loven et al. 2013; Alluri et al. 2014; Roe et al. 2015).
BET proteins can recognize acetylated lysine residues
on histones, but have also been increasingly found to
recognize acetylated non-histone proteins (Huang et al.
2009; Fujisawa & Filippakopoulos, 2017). BRD4 has been
demonstrated to localize genome-wide to promoter and
enhancer regions, with the majority of enhancer-bound
BRD4 found at a relatively small number of massive
enhancer regions termed super enhancers (SEs), akin to
locus control regions and also known as stretch enhancers,
which concentrate chromatin-bound coactivators to genes
essential for specialized cellular functions or lineage
specification (Nicodeme et al. 2010; Anand et al. 2013;
Chapuy et al. 2013; Loven et al. 2013; Parker et al. 2013;
Whyte et al. 2013; Brown et al. 2014). BET proteins
were initially described as having binding affinity to
acetyl-lysine on histone tails, but have subsequently been
shown to bind TFs and other chromatin associated
molecules via both BD-dependent and -independent
mechanisms (Huang et al. 2009; Asangani et al. 2014). The
therapeutic interest in the BET family was significantly
accelerated in 2010 with the development of small
molecule inhibitors of these proteins such as JQ1 and
iBET (Filippakopoulos et al. 2010; Nicodeme et al. 2010),
derivatives of which are progressing in early phase cancer
clinical trials (Andrieu et al. 2016). JQ1 is a first-in-class,
potent and specific thieono-triazolo-diazepine small
C© 2019 The Authors. The Journal of Physiology C© 2019 The Physiological Society
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molecule inhibitor of BET BDs that has exquisite shape
complementarity to the acetyl-lysine recognition pocket
of this protein family. JQ1 competitively and reversibly
displaces BET proteins from acetylated chromatin and
disrupts downstream chromatin-based signalling events.
JQ1 and related chemical probes have emerged as critical
tools that have accelerated our ability to probe BET
function in cells and model organisms (Filippakopoulos
et al. 2010).
BET bromodomains attenuate pathological cardiac
remodelling and ameliorate HF
In 2013, contemporaneous and independent studies
from our laboratory as well as Timothy McKinsey’s
group were the first to implicate BET family
proteins in stress-activated cardiac transcription and
HF pathogenesis (Anand et al. 2013; Spiltoir et al.
2013). JQ1 and several other structurally diverse BET
BD inhibitors were shown to block agonist-induced
cardiac hypertrophy and pathological gene induction
in vitro in neonatal rat ventricular myocytes (NRVMs)
with similar results achieved through siRNA-mediated
silencing of BRD4 (Anand et al. 2013). In pressure
overload-mediated (thoracic aortic constriction; TAC)
and neurohormone-mediated (chronic phenylephrine
infusion) murine models of HF pathogenesis, early JQ1
administration prevented adverse cardiac remodelling,
cardiac hypertrophy and HF. In these models, mice
treated with JQ1 had improved cardiac function and
attenuation of cardinal histopathological features of
HF (decreased cardiomyocyte hypertrophy, substantially
reduced myocardial fibrosis, and enhanced myocardial
capillary density) (Anand et al. 2013). Microarray-based
transcriptomic analysis of whole cardiac tissue from
this study revealed that BET inhibition suppressed the
activation of specific cardiac gene expression programmes
that enrich for targets of nuclear factor of activated
T cells (NFAT), nuclear factor-κB (NFκB) and GATA
binding protein 4 (GATA4) signalling (Anand et al. 2013).
Importantly, the targets of BETs in the murine TAC
model had statistical overlap with genes induced in left
ventricular (LV) tissue from patients with HF (Anand
et al. 2013). Analysis of genome-wide occupancy of BRD4
and Pol II in the hearts of TAC- or sham-operated mice
receiving JQ1or vehicle demonstrated that BRD4occupies
active cardiac enhancers, recruits P-TEFb activity to trans-
criptional start sites, and triggers pause-release of Pol
II to activate the expression of genes critical for HF
pathogenesis (Anand et al. 2013).
While these initial studies provided early insight
into BET protein function in HF, they relied on
early administration of JQ1 to prevent pathological
remodelling. Our group subsequently demonstrated the
therapeutic efficacy of JQ1 in the more clinically relevant
experimental setting of pre-established HF in both the
murine TAC and myocardial infarction (MI) models
(Duan et al. 2017). Importantly, JQ1 at the doses
used in this study did not predispose to LV rupture
after permanent left anterior descending coronary artery
(LAD) ligation. Transcriptomic analysis of LV tissue
from both the TAC and MI hearts revealed that the
common therapeutic effect of BET inhibition across
these HF models was to suppress transactivation of a
core gene regulatory network that robustly enriched
for targets of TGF-β and NFκB signalling, with a
strong signature of attenuating the myofibroblast gene
expression programme (Duan et al. 2017). This pre-
dilection for JQ1 to specifically suppress pro-fibrotic
and pro-inflammatory transcriptional networks led us
to hypothesize that JQ1 might be permissive to physio-
logical cardiac growth in response to exercise training,
a tissue remodelling process that does not typically
feature fibrosis and inflammation (Bostrom et al. 2010;
Maillet et al. 2013). We therefore tested JQ1 in a murine
model of physiological cardiac remodelling induced by
high intensity swim training and found that JQ1- and
vehicle-treated animals demonstrated similar increases
in cardiac mass, cardiomyocyte cross-sectional area and
cardiac function, suggesting that JQ1 administration
does not block exercise-induced cardiac plasticity (Duan
et al. 2017). To provide more human relevance, this
study also demonstrated that BET inhibition can block
endothelin-1-mediated cardiomyocyte hypertrophy and
NPPB induction in human induced pluripotent stem
cell (iPSC)-derived cardiomyocytes (CMs). Furthermore,
transcriptomic analysis in human iPSC-derived CMs
revealed that BET inhibition specifically suppressed a gene
programme that was also enriched for pro-inflammatory
and pro-fibrotic signalling effectors (Duan et al. 2017).
In the NRVM in vitro model, neurohormonal stress
(induced by phenylephrine treatment) leads to rapid
redistribution of BRD4 to distinct genomic loci that
regulate hypertrophic gene expression and suggests that
BRD4 protein abundance is restrained by a microRNA
(miR)-9 dependent signalling circuit (Stratton et al. 2016).
BET inhibition with JQ1 was recently demonstrated to
exert protective effects in streptozotocin-induced diabetic
cardiomyopathy in mice (Guo et al. 2018). It has also
been shown that BET BD inhibitors given at the time of an
acuteMI can acutely attenuate infarct size in rats, although
the mechanisms underlying this protective effect remain
unknown (Sun et al. 2015). Interestingly, Burke and
colleagueshave alsopresenteddata that JQ1canameliorate
HF and reduce mortality in a mouse model of human
dilated cardiomyopathy driven by CM-specific expression
of the mutant phospholamban-R9C gene (Schmitt et al.
2003; Burke et al. 2017), a model which features intense
activation of fibrotic and inflammatory gene programmes
early in the course of disease pathogenesis (Burke
C© 2019 The Authors. The Journal of Physiology C© 2019 The Physiological Society
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et al. 2016). Taken together, these data establish that
pharmacological administration of BETBD inhibitors can
have significant therapeutic effects in a diverse range of
small animal HF models via a mechanism that converges
on suppression of pro-fibrotic and pro-inflammatory
gene expression programmes in the heart. Indeed, this
may partially account for the absence of a JQ1-mediated
effect on exercise-induced cardiac growth in adult mice
(Duan et al. 2017), a form of tissue plasticity that
does not typically involve activation of inflammatory
or fibrotic transcriptional programmes (Maillet et al.
2013; Liu et al. 2015). Consistent with this finding, our
RNA-Seq data did not show a significant effect of JQ1
on inhibiting transcriptional programmes involved in
global protein synthesis. The known on-target toxicities
as well as potential off-target toxicities of BET inhibitors,
however, remain an important barrier to the further
translation of these drugs for chronic disease applications
in humans. In mice, JQ1 treatment affects the expression
of synaptic proteins and receptors in neurons with
functional effects on long-term memory and decreased
seizure susceptibility (Korb et al. 2015). Murine JQ1
treatment is also associated with reductions in spleen and
thymus weights (Wroblewski et al. 2018) as well as sperm
count and motility (Matzuk et al. 2012). In an inducible
transgenic RNA interference mouse model, systemic
BRD4 suppression in adult animals was associated with
toxicity in several organs including altered hematopoiesis,
follicular dysplasia, and decreased cellular diversity along
with stem cell depletion in the small intestine (Bolden
et al. 2014). Toxicity profiles from early clinical trials
with BET inhibition for haematological and solid tumours
have demonstrated thrombocytopenia, fatigue, nausea,
vomiting and diarrhoea (Doroshow et al. 2017). Indeed,
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Figure 1. Model for stimulus-dependent regulation of pathological cardiac gene expression via BRD4
Transcriptional activation involves the ‘reading’ function of BRD4, in which the bromodomains of BRD4 recognize
acetylated lysines (green dots) on histone tails at key enhancer regions. Preferential BRD4 enrichment at specific
enhancers is likely mediated via recruitment by DNA-binding transcription factors, possibly through direct inter-
actions with BRD4 or via indirect mechanisms (e.g. the TF-dependent recruitment of histone acetyltransferases
or other co-activator complexes to active chromatin). The labels X, Y and Z designate the putative co-activator
molecules that are recruited by enhancer bound TFs, which may include BRD4. Small molecule BET bromo-
domain inhibitors such as JQ1 function by reversibly disrupting the interactions of BET proteins with acetylated
histones or other chromatin-associated protein complexes. One major way that enhancer-bound BRD4 co-activates
transcription is via allosteric activation of the P-TEFb complex, which is required for the release of paused Pol II
during transcriptional elongation. Critical questions that remain to be answered focus on which cardiac cell types
are important for mediating the therapeutic effects of BET inhibitors, the specific BET family members that are
operative (i.e. BRD2, 3, or 4), and the identity of other putative members of these transcriptional complexes that
themselves may be druggable targets in HF. Red circles denote histone marks that designate inactive chromatin.
TSS, transcriptional start site; CM, cardiomyocyte; EC, endothelial cell; FB, fibroblast; myoFB, myofibroblast; M,
macrophage.
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these toxicities are likely to be intensified with the use
of small molecule compounds that mediate BET protein
degradation (Lu et al. 2015; Winter et al. 2015; Zengerle
et al. 2015; Raina et al. 2016). Efforts to create small
molecules with preferential binding to only one of the
tandem BD regions (Picaud et al. 2013; Zhang et al. 2013)
or to specific BET isoforms (Liu et al. 2018) may increase
the therapeutic index of BET inhibition.
Future directions
While JQ1 itself is a tool compound that lacks ideal
drug-like properties, other BET inhibitor drugs have
been developed, including derivatives of JQ1. These BET
inhibitor drugs are presently in clinical trials for various
malignancies and atherosclerosis, laying the potential
groundwork for broader applications in the future (Bailey
et al. 2010; Nicholls et al. 2011; Nicholls et al. 2012;
Andrieu et al. 2016; Gilham et al. 2016). However, many
critical therapeutic and mechanistic questions remain to
be answered (Fig. 1). JQ1 is a potent inhibitor of all
four BET proteins and the gene-specific effects of BRD2,
BRD3 and BRD4 in the heart have yet to be dissected
in vivo. It also remains unclear which cell types in the
heart are specifically driving the aforementionedbeneficial
effects of JQ1 in vivo. The generation of mice harbouring
conditional alleles of BRD2, BRD3 and BRD4, coupled
with inducible Cre drivers, will provide important insight
into these questions pertaining to gene- and cell-specific
effects in vivo. It is also rather remarkable that inhibition
of BRD4, an omnipresent enhancer protein, exerts a
specific effect on certain gene programmes during cardiac
stress. Understanding how genome-wide enrichment of
BRD4 dynamically changes in a locus-specific manner
during cardiac stress in vivo will enhance our mechanistic
understanding of enhancer-regulated gene control during
HF. Furthermore, identification of BRD4 protein inter-
action partners in specific cell types or disease contexts
will be critical for our mechanistic understanding of
target gene specificity and may pave the way for the
development of more tissue-restricted BET inhibitory
strategies. Such information, coupledwith amore detailed
structure–function analysis of different domains in BRD4,
may inform new ways to modulate BRD4 function (Jung
et al. 2014; Shi & Vakoc, 2014; Roe & Vakoc, 2016; Zhang
et al. 2016), possibly in a BD-independent manner.
The study of BET protein function in the heart
collectively supports the notion that interdicting upon
the final common pathway of stress-induced signalling
between enhancers and the transcription machinery may
broadly serve as a novel therapeutic strategy in HF.
Indeed, the regulation of the Pol II transcription cycle
is an intricate process involving several large multiprotein
complexes with several members harbouring enzymatic
activities. This suggests that there may be potential targets
beyond BRD4 that could similarly be manipulated for the
treatment of HF.
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